Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide low-dose continuous chemotherapy in WHO grade II low-grade glioma
2006-001545-34Phase 2Completed
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Apr 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in diffuse low-grade glioma (LGG), astrocytoma, oligoastrocytoma and 1 more, sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Progression-free survival at 12–24 months. Started Apr 2006; status: completed.
02
Drugs
temozolomide
03
Conditions
diffuse low-grade glioma (LGG)astrocytomaoligoastrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on 2006-001545-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001545-34.